Targeting HTLV-1 Tax: Towards a Therapeutic Strategy for HTLV-1- Associated Diseases.
Abstract
Human T-cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that belongs to the family Retroviridae and the genus Deltaretrovirus. HTLV-1 infection is linked to acute and chronic illnesses, including adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and other inflammatory disorders. This overview focuses on the molecular biology of HTLV-1, with particular emphasis on viral structure and genome organization, as well as the roles of key viral proteins in replication and pathogenesis. Special attention is given to the viral regulatory proteins Tax and HTLV-1 basic leucine zipper factor (HBZ), which drive cellular transformation, immune dysregulation, viral persistence, and disease progression. This review examines the oncogenic role of the Tax protein and its potential contribution to the immunopathogenesis of HAM/TSP. Furthermore, it summarizes current and novel therapeutic strategies against HTLV-1-associated diseases, focusing on antiretroviral therapy, immunomodulatory approaches, and Tax-targeted therapies. Challenges in clinical translation and limitations of current treatments are also discussed. This review covers most facets of HTLV-1 biology, pathogenesis, and treatment strategies, with the overall message that more studies are warranted for effective targeted therapies and disease management.